Aquestive Therapeutics, INC

Aquestive Therapeutics announced positive topline results from human factors and pharmacokinetic studies for its Anaphylm sublingual film, supporting a planned New Drug Application resubmission to the FDA.

Aquestive Therapeutics, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and the ratification of its independent auditor.

Aquestive reports a successful FDA Type A meeting for Anaphylm, aligns on study designs, and reaffirms an NDA resubmission target in Q3 2026.

Aquestive Therapeutics announced the appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer, succeeding Lori J. Braender, who will transition to Corporate Secretary.

Aquestive Therapeutics reported Q4 and full-year 2025 financial results, extended its revenue sharing agreement with RTW, and outlined a plan to address the FDA's Complete Response Letter for Anaphylm.

Aquestive Therapeutics received a Complete Response Letter for Anaphylm, delaying its approval, but plans a Q3 2026 resubmission backed by a strong cash position.

Aquestive Therapeutics announces the termination of an executive employment agreement, with the executive transitioning to Corporate Secretary.

Aquestive Therapeutics reported a significant increase in net loss and revenue decline for Q3 2025, while its lead product candidate Anaphylm progresses towards a January 2026 FDA decision, and Libervant's U.S. market access was vacated by a court ruling.

Aquestive Therapeutics, Inc. reported a significant increase in net loss and a substantial decline in revenue for the second quarter and first half of 2025, primarily due to one-time revenue recognition in the prior year and the halted U.S. market access for Libervant, while its Anaphylm NDA was accepted by the FDA with a January 2026 PDUFA date.

Aquestive Therapeutics announces its Q1 2025 financial results and provides an update on its key product candidates, including the submission of the NDA for Anaphylm.

Aquestive Therapeutics' Q3 2024 results show a 22% year-to-date revenue increase, driven by license and royalty revenue, despite a decrease in manufacturing revenue.

Aquestive Therapeutics saw a significant revenue increase in Q2 2024, driven by one-time gains, despite a decrease in manufacturing revenue.

Aquestive Therapeutics reports a significant net loss increase and a delay in Anaphylm's FDA approval, alongside a legal setback for Libervant, despite successful capital raises.

Aquestive Therapeutics' 2024 results highlight progress in proprietary pipeline development alongside challenges in commercial execution and a significant legal hurdle for its newly launched Libervant.

Aquestive Therapeutics amended its license agreement with Pharmanovia to expand the territory for Libervant and filed an NDA for pediatric use of the drug.

Sherry Korczynski, Chief Commercial Officer of Aquestive Therapeutics, Inc., reported a transaction in 2,714 shares of common stock on August 14, 2026.

Daniel Barber, President and CEO of Aquestive Therapeutics, Inc., sold 25,000 shares of common stock on July 15, 2026.

Aquestive Therapeutics Director Julie Krop executed a Rule 10b5-1 trading plan, exercising options and selling shares.

Aquestive Therapeutics President and CEO Daniel Barber reported a sale of 25,000 shares of common stock.

Director Timothy E. Morris was granted 50,500 stock options in Aquestive Therapeutics, Inc. as part of a standard equity incentive.

Director Julie Krop was granted 50,500 stock options in Aquestive Therapeutics, Inc. as part of a standard equity compensation plan.

Aquestive Therapeutics announces its 2026 Annual Meeting of Stockholders to be held virtually on June 10, 2026.

Aquestive Therapeutics, Inc. has filed a definitive proxy statement with the SEC.

Aquestive Therapeutics will hold its 2025 Annual Meeting of Stockholders virtually on June 11, 2025, to vote on director elections, executive compensation, and the ratification of the company's accounting firm.

Aquestive Therapeutics, Inc. has filed a definitive proxy statement with the SEC.

Aquestive Therapeutics announces its 2024 Annual Meeting of Stockholders to be held virtually on June 20, 2024, to vote on director elections, executive compensation, and auditor ratification.

RTW Investments, LP and Roderick Wong, M.D. have reported a 5.2% beneficial ownership stake in Aquestive Therapeutics, Inc. as of September 30, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 5.3% passive ownership stake in Aquestive Therapeutics Inc. common stock.

Venrock Healthcare Capital Partners and its affiliated entities have filed an amended Schedule 13G, disclosing a beneficial ownership of 2.9% in Aquestive Therapeutics, Inc. as of December 31, 2024.

Douglas K. Bratton and a group of affiliated investment entities have filed an updated Schedule 13G, disclosing a combined beneficial ownership of 11.1% in Aquestive Therapeutics, Inc.'s common stock as of December 31, 2024.